Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

34.67
+0.02790.08%
Volume:1K
Turnover:37.47K
Market Cap:44.20M
PE:- -
High:34.68
Open:34.59
Low:34.53
Close:34.64
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.31
T/O Rate:0.08%
Dividend:0.08
Dividend Rate:0.22%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Rhythm Pharma Says Japan Regulator Approves Imcivree for Acquired Hypothalamic Obesity

Reuters
·
Aug 24

Rhythm Pharmaceuticals, - Imcivree Launch in Japan Expected by End of 2026 Pending Pricing

THOMSON REUTERS
·
Aug 24

Roche, Eli Lilly's Alzheimer's Blood Test Gets FDA Clearance

Reuters
·
Aug 24

EU Commission Approves Gilead Trodelvy-Keytruda Combo for First-Line PD-L1+ Metastatic TNBC

Reuters
·
Aug 24

Gilead - EU Grants Marketing Authorization for Trodelvy with Keytruda in First-Line Pd-L1-Positive Metastatic Tnbc

THOMSON REUTERS
·
Aug 24

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across Pd-L1 Status

THOMSON REUTERS
·
Aug 24

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 24

Eli Lilly: Working with Nice on Assessment of Foundayo for Potential Use on Nhs in England

THOMSON REUTERS
·
Aug 24

Eli Lilly Launches Oral Weight-Loss Pill Foundayo in UK

Reuters
·
Aug 24

Eli Lilly: Foundayo NOW Available in UK to be Prescribed for Eligible Adults Via Private Prescription

THOMSON REUTERS
·
Aug 24

Eli Lilly: in UK, Foundayo is Priced Lower than Mounjaro; Likely to be in Order of £100 to £120

THOMSON REUTERS
·
Aug 24

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity

Simply Wall St.
·
Aug 22

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Aug 22

Gilead Director Jeffrey Bluestone Disposes of 5,000 Common Shares Worth $727,333.60

Reuters
·
Aug 22

Moderna Inc. Stock Advances 8.9%, Outperforms Peers

Dow Jones
·
Aug 22

Gilead Declares Q3 2026 Dividend of R$ 0.24 Per Unit

Reuters
·
Aug 22

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

TIPRANKS
·
Aug 22

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

TIPRANKS
·
Aug 22

Pharma Stocks Have Rallied. 2 Stocks to Avoid-and 2 to Buy.

Dow Jones
·
Aug 21

Gilead (GILD) Stock Still Looks Below Fair Value As Court Backs HIV Import Block

Simply Wall St.
·
Aug 21